菲内伦在拉丁裔患者中患有CKD和2型糖尿病:后期可信度分析
Sylvia E Rosas1, Luis M Ruilope2, Stefan D Anker3,4
1Kidney and Hypertension Unit, Joslin Diabetes Center and Harvard Medical School, Boston, MA.
Kidney medicine
|September 25, 2023
概括
与非西班牙裔患者相比,芬瑞在患有慢性病和2型糖尿病的西班牙裔患者中表现出类似的疗效和安全性. 这种治疗在不同的人群中提供了可比的心脏脏益处.
科学领域:
- 脏病学和内分泌学
- 心血管医学 心血管医学
- 临床试验分析
背景情况:
- 慢性病 (CKD) 和2型糖尿病 (T2D) 不成比例地影响西班牙裔人口,往往有更积极的进展.
- 芬瑞诺在T2D患者中显示出心脏和脏的益处,但在特定种族群体 (如西班牙裔) 中的数据不那么强大.
- 了解不同人群的治疗疗效和安全性对于公平的医疗保健至关重要.
研究的目的:
- 评估菲内伦在患有CKD和T2D的西班牙裔患者的疗效和安全性.
- 在西班牙裔和非西班牙裔患者子组之间比较心结局和尿动白蛋白与肌素比率 (UACR) 变化.
- 评估不同种族群体中fineerenone的益处的一致性.
主要方法:
- 对FIDELITY的后期分析,从FIDELIO-DKD和FIGARO-DKD随机对照试验中汇总了数据.
- 包括患有T2D和CKD的患者,接受优化氨酸-血管新生系统阻塞.
- 评估了心血管综合结果,综合结果和UACR变化,在西班牙裔和非西班牙裔群体中比较芬瑞诺与安慰剂.
主要成果:
- 与安慰剂相比,芬瑞在西班牙裔患者 (HR,0.80;95% CI,0.62-1.04) 中显示出一致的心血管益处,与非西班牙裔患者相似 (HR,0.87;95% CI,0.79-0.97).
- 在西班牙裔 (HR,0.94;95% CI,0.67-1.33) 和非西班牙裔患者 (HR,0.75;95% CI,0.64-0.87) 之间,综合结局也相似.
- 在西班牙裔患者中,芬瑞显著降低了32%的UACR,反映了非西班牙裔群体的效应. 包括高血症在内的安全概况在各组中相似.
结论:
- 芬瑞诺在改善心脏结结果和减少UACR方面表现出与非西班牙裔患者观察到的CKD和T2D的西班牙裔患者相似的疗效.
- 在西班牙裔和非西班牙裔人口中,芬瑞的安全性概况是一致的.
- 这些发现支持使用finerenone作为西班牙裔CKD和T2D患者的治疗选择.
相关概念视频
01:11Renal Failure: Dose Adjustments
109
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
109
01:17Factors Affecting Renal Clearance: Renal Impairment
114
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
114
01:28Chronic Kidney Disease III: Interprofessional Care
28
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
28
01:06Renal Drug Clearance: Overview
240
Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
240
01:15Renal Drug Excretion: Overview
178
As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules...
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules...
178
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
454
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
454